PROSTATE CANCER (PC) The Prostate Cancer (PC) Program aims to advance scientific knowledge that will reduce the morbidity and mortality attributed to PC and lead to improvements in patients? quality of life. The PC Program has three primary aims: (1) Develop approaches for determining early stage PC risk, optimizing detection strategies, and deploying risk-based interventions; (2) Advance the molecular understanding of the androgen receptor signaling program to inform the rational design of therapeutic strategies for treating high-risk localized and metastatic PC; and (3) Evolve therapeutic approaches for the treatment of PCs directed toward inhibiting key oncogenic (intrinsic) drivers and modulating components of the tumor microenvironment. The PC Program has 42 members based at the University of Washington (UW) or Fred Hutch (FH), with clinical practice sites at the UW, Seattle Cancer Care Alliance (SCCA), and Veterans Administration (VA) Puget Sound Health Care System. Nine PC members have primary appointments at FH and 33 members at UW spanning 11 Departments and Divisions. Ten members joined this program since the last cycle. The current research portfolio of PC members is $11.6M (direct costs), of which $8.6M is peer-reviewed funding, including $2M from the NCI. A substantial component of the research funding is in the form of P50, P01, U54 and other collaborative grants. The Prostate Cancer program members published a total of 558 papers in the current grant period, of which 31% were intra-programmatic, 22% were inter-programmatic, and 56% had external co-authors. Eleven out of 12 Consortium Shared Resources were utilized by PC members in the course of their work. In addition to providing key shared resources, in particular Comparative Medicine, Genomics & Bioinformatics, and Research Pathology Shared Resources, the P30 CCSG supports this research program by providing administrative and logistical support for PC Program meetings; pilot funding for new research projects; and recruitment of new faculty.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015704-46
Application #
10125974
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-01-01
Project End
2024-12-31
Budget Start
2021-01-01
Budget End
2021-12-31
Support Year
46
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Briant, Katherine J; Sanchez, Janeth I; Ibarra, Genoveva et al. (2018) Using a Culturally Tailored Intervention to Increase Colorectal Cancer Knowledge and Screening among Hispanics in a Rural Community. Cancer Epidemiol Biomarkers Prev 27:1283-1288
Xu, Chang; Nikolova, Olga; Basom, Ryan S et al. (2018) Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer. Clin Cancer Res 24:2828-2843
Miller, Chris P; Tsuchida, Connor; Zheng, Ying et al. (2018) A 3D Human Renal Cell Carcinoma-on-a-Chip for the Study of Tumor Angiogenesis. Neoplasia 20:610-620
Baker, K Scott; Syrjala, Karen L (2018) Long-term complications in adolescent and young adult leukemia survivors. Hematology Am Soc Hematol Educ Program 2018:146-153
Gavvovidis, Ioannis; Leisegang, Matthias; Willimsky, Gerald et al. (2018) Targeting Merkel Cell Carcinoma by Engineered T Cells Specific to T-Antigens of Merkel Cell Polyomavirus. Clin Cancer Res 24:3644-3655
Paulson, K G; Voillet, V; McAfee, M S et al. (2018) Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA. Nat Commun 9:3868
Puronen, Camille E; Cassaday, Ryan D; Stevenson, Philip A et al. (2018) Long-Term Follow-Up of 90Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation-Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma. Biol Blood Marrow Transplant 24:2211-2215
Witzky, Anne; Hummels, Katherine R; Tollerson 2nd, Rodney et al. (2018) EF-P Posttranslational Modification Has Variable Impact on Polyproline Translation in Bacillus subtilis. MBio 9:
Rosenthal, Elisabeth A; Shirts, Brian H; Amendola, Laura M et al. (2018) Rare loss of function variants in candidate genes and risk of colorectal cancer. Hum Genet 137:795-806
Verboon, Jeffrey M; Decker, Jacob R; Nakamura, Mitsutoshi et al. (2018) Correction: Wash exhibits context-dependent phenotypes and, along with the WASH regulatory complex, regulates Drosophila oogenesis (doi:10.1242/211573). J Cell Sci 131:

Showing the most recent 10 out of 1267 publications